Tralesinidase alfa ERT for Sanfilippo type B children put on fast track
Tralesinidase alfa, also known as TA-ERT, Spruce Biosciences’ investigational enzyme replacement therapy (ERT) for children with Sanfilippo syndrome type B, has received breakthrough therapy designation from the U.S. Food and Drug Administration (FDA). The designation is intended to speed up the development and review of treatments that show early evidence…